Cardiome Pharma names Algorithm as North African distributor for investigational drug

drugsCardiome Pharma's commercial sale and distributors agreement with Algorithm for the BRINAVESS drug is for a period of five years. (Image source: Wolfman.K/Flickr)US-based Cardiome Pharma has named Lebanon's Algorithm as the exclusive seller and distributor for its intravenous investigational drug BRINAVESS, in certain parts of North Africa and the Middle East

Cardiome Pharma did not disclose the financial terms of the agreement with Algorithm.  

In a company statement, Cardiome Pharma said the commercial sale and distributors agreement with the pharmaceutical manufacturer, which is effective from November 2013, would run for a period of five years.

The drug, which is used to investigate heart disorders, would be sold in Algeria, Bahrain, Egypt, Iran, Jordan, Saudi Arabia, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Tunisia and the UAE.

Cardiome Pharma chief commercial officer Karim Lalji said, “We are pleased to have entered into this agreement with Algorithm. We look forward to continuing the commercialisation of BRINAVESS in approved markets.”

Algorithm human health lead officer Nabil Ghorayeb added, “Our company has a long and successful history in the cardiovascular market and BRINAVESS is an excellent addition to our product portfolio that would offer customers a treatment option for the early onset of atrial fibrillation.”

Alain Charles Publishing, University House, 11-13 Lower Grosvenor Place, London, SW1W 0EX, UK
T: +44 20 7834 7676, F: +44 20 7973 0076, W:

twn Are you sure that you want to switch to desktop version?